Payment overview · 2025
General Payments
$267,411.86
321 reported records · 14 companies
Healthcare provider profile · identity verified
David A Clark, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SPRINGFIELD, OR · NPI 1578760278
Verified facts
What the public records show
CMS Open Payments records show David A Clark, DO received $267,411.86 in general payments during 2025 across 321 reported records.
TG Therapeutics, Inc. accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Nurtec Odt, Qulipta, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ubrelvy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Vumerity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Nurtec Odt by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $54,712.19 | 20.5% | 38 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $40,189.53 | 15.0% | 48 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36,247.48 | 13.6% | 50 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $35,427.29 | 13.2% | 54 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $32,730.62 | 12.2% | 52 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $30,902.87 | 11.6% | 24 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $22,244.83 | 8.3% | 23 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $11,655.89 | 4.4% | 14 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $3,050.16 | 1.1% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $150.47 | 0.1% | 7 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $35.22 | 0.0% | 2 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $27.54 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.77 | 0.0% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $18.00 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $217,921.25 | 68 |
| Travel and Lodging | $32,006.29 | 112 |
| Consulting Fee | $12,004.00 | 9 |
| Food and Beverage | $5,480.32 | 132 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $54,712.19 | 38 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $32,966.22 | 47 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $30,836.54 | 40 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $27,152.87 | 19 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $19,124.25 | 27 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $16,303.04 | 27 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $10,150.75 | 14 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $7,731.27 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $3,913.82 | 7 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $3,579.00 | 4 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $3,050.16 | 6 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $144.08 | 11 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $48.58 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $35.22 | 2 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $27.54 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 111 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
111 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 350 | 94 |
| Baclofen | Baclofen | 214 | 49 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 167 | 48 |
| Prednisone | Prednisone | 166 | 42 |
| Vumerity | Diroximel Fumarate | 111 | 12 |
| Topiramate | Topiramate | 109 | 22 |
| Teriflunomide | Teriflunomide | 97 | 16 |
| Kesimpta Pen | Ofatumumab | 91 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 89 | 37 |
| Levetiracetam | Levetiracetam | 78 | 22 |
| Modafinil | Modafinil | 78 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 17 |
| Sumatriptan Succinate | Sumatriptan Succinate | 61 | 15 |
| Donepezil Hcl | Donepezil Hcl | 59 | 13 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 58 | suppressed |
| Primidone | Primidone | 57 | 15 |
| Dalfampridine Er | Dalfampridine | 56 | suppressed |
| Pregabalin | Pregabalin | 55 | 12 |
| Aimovig Autoinjector | Erenumab-Aooe | 52 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 50 | 20 |
| Dimethyl Fumarate | Dimethyl Fumarate | 47 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 45 | 11 |
| Trazodone Hcl | Trazodone Hcl | 44 | 12 |
| Propranolol Hcl | Propranolol Hcl | 43 | 13 |
| Glatiramer Acetate | Glatiramer Acetate | 41 | suppressed |
| Fingolimod | Fingolimod Hcl | 40 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 36 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 35 | suppressed |
| Diazepam | Diazepam | 34 | 16 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 30 | suppressed |
| Amantadine | Amantadine Hcl | 29 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 29 | suppressed |
| Avonex (4 Pack) | Interferon Beta-1a | 29 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 28 | suppressed |
| Carbamazepine Er | Carbamazepine | 28 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 28 | suppressed |
| Qulipta | Atogepant | 28 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 27 | suppressed |
| Lacosamide | Lacosamide | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Glatopa | Glatiramer Acetate | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Carisoprodol | Carisoprodol | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Ubrelvy | Ubrogepant | 19 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Botox | Onabotulinumtoxina | 15 | suppressed |
| Copaxone | Glatiramer Acetate | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 13 | suppressed |
| Briviact | Brivaracetam | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Mayzent | Siponimod | 12 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Betaseron | Interferon Beta-1b | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Lamotrigine Er | Lamotrigine | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Rebif Rebidose | Interferon Beta-1a/Albumin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267,411.86 · 321 records | TG Therapeutics, Inc. | BOTOX, BRIUMVI, EPIDIOLEX, NURTEC ODT, PONVORY, QULIPTA, Rystiggo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYEPTI, VYVGART, VYVGART HYTRULO, ZAVZPRET, Zilbrysq | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error